



Press release, November 21, 2019

## **Bulletin from Annual General Meeting of Diamyd Medical AB**

The Annual General Meeting of Diamyd Medical AB (publ) was held on November 21, 2019.

The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2018/2019. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2018/2019.

Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller, Maria-Teresa Essen-Möller, Torbjörn Bäckström and Mark A. Atkinson were re-elected to the Board.

The Annual General Meeting approved the proposed remuneration to Board members and the Chairman of the Board.

The Annual General Meeting resolved to re-elect the auditing company BDO until the end of the Annual General Meeting 2020. Principal auditor is the authorized public accountant Johan Pharmanson.

The Annual General Meeting resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting to issue shares and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.

### **About Diamyd Medical**

Diamyd Medical develops the diabetes vaccine Diamyd<sup>®</sup>, as an antigen-specific immunotherapy for the preservation of endogenous insulin production. Diamyd<sup>®</sup> has demonstrated good safety in trials encompassing more than 1,000 patients as well as effect in certain pre-specified subgroups. In addition, besides the Company's own European Phase IIb trial DIAGNODE-2 where the diabetes vaccine is administered directly into a lymph node, two investigator initiated clinical trials are ongoing with Diamyd<sup>®</sup>. Diamyd Medical also develops the GABA-based investigational drug Remygen<sup>®</sup> for regeneration of endogenous insulin production. An investigator-initiated Remygen<sup>®</sup> trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: [info@fnca.se](mailto:info@fnca.se).

### **For further information, please contact:**

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41

E-mail: [ulf.hannelius@diamyd.com](mailto:ulf.hannelius@diamyd.com)

### **Diamyd Medical AB (publ)**

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68

E-mail: [info@diamyd.com](mailto:info@diamyd.com) Reg. no.: 556242-3797 Website: <https://www.diamyd.com>

**Publication**

The information was submitted for publication, through the agency of the contact person set out above, at 18.25 CET on November 21, 2019.